- Once erythropoiesis-stimulating agents are started, they should
be continued unless the patient’s hemoglobin level is above the desired
- These agents actually decrease the survival rate, due to the
increased risk of myocardial infarction, stroke, heart failure, blood
clots, and increased tumor growth rates.
- The hemoglobin target in renal dialysis patients = 11.0 g/dL.
A higher hemoglobin target may actually increase mortality rates. The
target hemoglobin rate for chronic kidney disease patients who are not
on dialysis is the same as for dialysis patients.
- Once the hemoglobin target has been reached in patients with chronic
kidney disease, the medications should be continued at a lower